Gilead Settles Teva HIV Drug Patent Suit to Avoid Trial

Teva Pharmaceuticals and Gilead Sciences Inc. agreed to settle a patent dispute over Viread, a treatment for HIV infection and chronic Hepatitis B, avoiding a trial that was scheduled to start today, Gilead said.

Teva will be permitted to begin sales of a generic version of Viread on Dec. 15, 2017, Gilead said in a statement distributed by Business Wire.

“We believe strongly in the validity of our intellectual property,” John Milligan, Gilead’s president, said in the statement yesterday. “This settlement, however, removes some uncertainty and minimizes further distraction.”

Gilead, based in Foster City, California, sued Teva in 2008 and again in 2010, claiming that Teva’s applications to the U.S. Food and Drug Administration to make drugs to treat HIV infections in adults infringed four of its patents. The trial in New York has been adjourned until the completion of the settlement agreement, Gilead said.

Teva, based in Petach Tikva, Israel, had said in court papers that Gilead’s patents were invalid and therefore couldn’t be infringed.

The case is Gilead Sciences v. Teva Pharmaceuticals USA, 10-01796, U.S. District Court, Southern District of New York (Manhattan).

To contact the reporter on this story: Joe Schneider in Sydney at jschneider5@bloomberg.net

Photographer: JB Reed/Bloomberg

Gilead Sciences Inc.'s Viread AIDS medication is arranged for a photo at Ansonia Pharmacy in New York. Close

Gilead Sciences Inc.'s Viread AIDS medication is arranged for a photo at Ansonia Pharmacy in New York.

Close
Open
Photographer: JB Reed/Bloomberg

Gilead Sciences Inc.'s Viread AIDS medication is arranged for a photo at Ansonia Pharmacy in New York.

To contact the editor responsible for this story: Douglas Wong at dwong19@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.